Implications of Tamoxifen Resistance in Palbociclib Efficacy for Patients with Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer: Subgroup Analyses of KCSG-BR15-10 (YoungPEARL)

PURPOSE: YoungPEARL (KCSG-BR15-10) trial demonstrated a significant progression-free survival (PFS) benefit for premenopausal patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2−) metastatic breast cancer (MBC) for palbociclib plus exemestane with ovar...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Cancer Res Treat
Glavni autori: Lee, Jiyun, Im, Seock-Ah, Kim, Gun Min, Jung, Kyung Hae, Kang, Seok Yun, Park, In Hae, Kim, Jee Hyun, Ahn, Hee Kyung, Park, Yeon Hee
Format: Artigo
Jezik:Inglês
Izdano: Korean Cancer Association 2021
Teme:
Original Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8291192/
https://ncbi.nlm.nih.gov/pubmed/33332933
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4143/crt.2020.1246
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items